Drug Approval | August 31, 2023
Strides receives USFDA approval for Mycophenolate Mofetil for oral suspension
The approval bolsters the company's Mycophenolate Mofetil portfolio
The approval bolsters the company's Mycophenolate Mofetil portfolio
The company has new projects in development in Mumbai, Punjab, central and northern India, among others
DKSH has further fortified its strategic partnership with Biolin Scientific, a globally recognized pioneer in surface science instrumentation, across nine key markets in the APAC region
Aiming to establish a state-of-the-art healthcare facility in India that integrates the latest technologies, exceptional patient comfort, and optimal clinical outcomes
The company through its IPO will fetch Rs 1475.26 crore - Rs 1550.59 crore at the lower and upper end of the price band.
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
Application being reviewed under the FDA Project Orbis framework, which enables concurrent reviews among US, Australia, Canada, Switzerland, Singapore and United Kingdom health authorities
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
With a focus on optimizing patient experience with next-generation oral dosage forms, the US facility complements the cutting-edge research activities of Roquette’s existing pharma innovation centers in France and Singapore
Subscribe To Our Newsletter & Stay Updated
